Preclinical Evaluation of Novel CD33-Targeting Therapeutics for Treatment of Acute Myeloid Leukemia (AML)
- To determine, in vitro, the cytotoxic activity of novel CD33-targeting immunoconjugate
agents in cell samples from patients with acute myeloid leukemia (AML).
- To define the characteristics of AML cells responding to or resisting these agents.
OUTLINE: Cell samples are thawed and used for in vitro studies to determine the cytotoxic
activity of novel CD33-targeting immunoconjugate agents, including gemtuzumab ozogamicin,
for genotyping characterization by flow cytometry-based assays and/or western blot, and
colony-forming cell assays.
Activity of novel CD33-targeting immunoconjugate agents
Soheil Meshinchi, MD
Fred Hutchinson Cancer Research Center
United States: Federal Government